Literature DB >> 10660138

Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas").

G Qvigstad1, S Falkmer, B Westre, H L Waldum.   

Abstract

AIMS: The aims of this study were to illustrate the malignant potential of gastric enterochromaffin-like (ECL) cell carcinoids (ECLomas) associated with hypergastrinemia, and the gradual neoplastic progression of such tumours. In addition, we examined whether the tyramide signal amplification (TSA) technique could visualize immunohistochemical (IHC) neuroendocrine (NE) features in the dedifferentiated neoplastic ECL cells which were not detected by conventional methods.
METHODS: Conventional histopathological and IHC methods for visualizing ECL cells and cell proliferation were used in addition to the TSA technique. OBSERVATIONS: Our patient was followed for 5 years. During that period, her ECLoma displayed all the signs of classical tumour progression, ultimately with the appearance of metastases in the regional lymph nodes, the liver and the skin. The neoplastic ECL cells became progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there was a substantial decrease in argyrophil and IR NE cells that could be visualized by conventional methods. By applying the TSA technique, however, the number of IR tumour cells increased considerably.
CONCLUSIONS: ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumour progression. Such ECLomas deserve early, active, radical surgical treatment. The TSA technique is a valuable tool for visualizing the characteristic IHC features in dedifferentiated NE cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10660138     DOI: 10.1111/j.1699-0463.1999.tb01513.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  18 in total

1.  Indications for a neuroendocrine tumor-carcinoma sequence.

Authors:  H L Waldum; G Qvigstad; S Falkmer
Journal:  Virchows Arch       Date:  2001-08       Impact factor: 4.064

2.  Hypergastrinaemia in patients infected with Helicobacter pylori treated with proton pump inhibitors.

Authors:  H L Waldum
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 3.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

Authors:  Malcolm Boyce; Sally Dowen; Gillian Turnbull; Frans van den Berg; Chun-Mei Zhao; Duan Chen; James Black
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

Review 5.  Somatostatin analogs for gastric carcinoids: For many, but not all.

Authors:  Sara Massironi; Alessandra Zilli; Dario Conte
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

6.  Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Authors:  Andreas Tartaglia; Guida M Portela-Gomes; Kjell Oberg; Paolo Vezzadini; Maria P Foschini; Mats Stridsberg
Journal:  Virchows Arch       Date:  2006-01-12       Impact factor: 4.064

7.  Proton pump inhibitors on pancreatic cancer risk and survival.

Authors:  Malcolm D Kearns; Ben Boursi; Yu-Xiao Yang
Journal:  Cancer Epidemiol       Date:  2017-01-02       Impact factor: 2.984

Review 8.  Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach.

Authors:  Helge L Waldum; Øyvind Hauso; Øystein F Sørdal; Reidar Fossmark
Journal:  Dig Dis Sci       Date:  2014-12-06       Impact factor: 3.199

Review 9.  Animal models to study the role of long-term hypergastrinemia in gastric carcinogenesis.

Authors:  Reidar Fossmark; Gunnar Qvigstad; Tom Chr Martinsen; Øyvind Hauso; Helge L Waldum
Journal:  J Biomed Biotechnol       Date:  2010-11-24

10.  Cytotoxicity of streptozotocin on neuroendocrine cells of the pancreas and the gut.

Authors:  O Brenna; G Qvigstad; E Brenna; H L Waldum
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.